Evidence map›Paper›PMID 41553596›Full record

ArticleJournal of neuro-oncology2026

Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial.

Fabio Y Moraes, Jonah Isen, James Perry, Norm Laperriere, Alba A Brandes, Johan Menten, Claire Phillips, Mike Fay, Ryo Nishikawa, Warren P Mason and 4 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Fabio Y MoraesDepartment of Oncology, Queen's University, Kingston, ON, Canada. Fabio.YnoedeMoraes@kingstonhsc.ca.
Jonah IsenFaculty of Health Sciences, Queen's University, Kingston, ON, Canada.
James PerryOdette Cancer Centre, Sunnybrook Health Sciences, University of Toronto, Toronto, ON, Canada.
Norm LaperriereDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Alba A BrandesAzienda Unità Sanitaria Locale- Istituto di Ricovero e Cura a Carattere Scientifico Istituto delle Scienze Neurologiche, Bologna, Italy.
Johan MentenUniversity Hospital Gasthuisberg, Leuven, Belgium.
Claire PhillipsPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Mike FayUniversity of Newcastle, Newcastle, NSW, Australia.
Ryo NishikawaSaitama Medical University International Medical Center, Saitama, Japan.
Warren P MasonDepartment of Medicine, Divisions of Neurology and Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
J Greg CairncrossDepartment of Oncology, University of Calgary, Calgary, AB, Canada.
Wilson RoaDepartment of Oncology, University of Alberta and Cross Cancer Institute, Edmonton, AB, Canada.
Keyue DingDepartment of Public Health Sciences, Queen's University, Kingston, ON, Canada.
Chris O'CallaghanCanadian Cancer Trials Group, Kingston, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma (GB) in the elderly is associated with poor prognosis and outcome heterogeneity. We aimed to develop and validate prognostic nomograms for elderly GB patients using data from the CCTG CE.6 trial.

methodsData from 562 patients (≥ 65 years) randomized to radiotherapy alone (RT) or radiotherapy plus temozolomide (RT + TMZ) were divided into training and testing cohorts (3:2 ratio). Cox regression identified prognostic factors associated with overall survival (OS), which were integrated into multivariable models. Nomograms were constructed, internally validated, and used to stratify patients into risk groups. Kaplan–Meier survival estimates and log-rank tests assessed model performance.

resultsIn the RT + TMZ cohort, low MMSE, biopsy-only resection, male sex, and MGMT status unknown were independently associated with poorer OS. Median OS in training data was 5.7, 10.9, and 13.8 months for high-, middle-, and low-risk groups, respectively, with comparable results in validation (6.6, 9.9, and 13.1 months). PFS stratification also showed significant differences (median 3.3, 6.0, and 7.6 months). For the RT-alone arm, biopsy-only resection and male sex were prognostic, with risk groups demonstrating significant OS and PFS differences.

conclusionsTrial-based nomograms were developed and validated for elderly GB patients, effectively stratifying risk and predicting survival. These tools may guide individualized prognostication, inform treatment decisions, and improve trial design in this underrepresented population.

Indexed as

Brain NeoplasmsChemoradiotherapyGlioblastomaNomogramsAgedAged, 80 and overAntineoplastic Agents, AlkylatingFemaleFollow-Up StudiesHumansMalePrognosisRandomized Controlled Trials as TopicSurvival RateTemozolomideAntineoplastic Agents, AlkylatingTemozolomideChemoradiotherapyElderly patientsGlioblastomaNomogramPrognostic factorsSurvival

Identifiers

PMID41553596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.